Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Granulocyte Macrophage-Colony Stimulating Factor Protects Mice from the Flu

By LabMedica International staff writers
Posted on 05 May 2011
A study conducted on several different populations of mice found that that pulmonary administration of granulocyte macrophage-colony stimulating factor (GM-CSF) significantly reduced flu symptoms and prevented death after challenge with a lethal dose influenza virus.

GM-CSF protein is a cytokine that controls the production, differentiation, and function of granulocytes and macrophages. More...
Alveolar macrophages (AM), which are enhanced by GM-CSF, are essential to the innate immune response and have been shown to contribute to host defense against flu infections in various animal models.

In the current study, investigators at the University of Texas Health Science Center (Tyler, USA) worked with three groups of mice: a normal wild type control group, a line that had been genetically engineered to lack the gene for GM-CSF, and a line that had the GM-CSF gene in one lung only. Animals from each group were infected with influenza virus in an initial series of experiments.

Results published in the April 7, 2011, online edition of the American Journal of Respiratory and Critical Care Medicine revealed that after progressive weight loss, all the wild type and GM-CSF null mice died within days. In contrast, all the mice carrying the GM-CSF gene survived, and these animals gained back the weight they had initially lost after a short period of time. The resistance of the transgenic mice to influenza was canceled by elimination of alveolar macrophages, but not by depletion of T-cells, B-cells, or neutrophils.

In a second series of experiments, animals were given GM-CSF after having been infected with the flu virus. Delivery of intranasal GM-CSF to the wild type mice conferred resistance to influenza to these animals. This resistance was apparently due to the enhancement of innate immune mechanisms that depend on alveolar macrophages.

"Such unique and unambiguous results demonstrate the great potential of GM-CSF and may be the remedy for a critical public health priority: developing strategies to reduce the morbidity and mortality from influenza,” said senior author Dr. Homayoun Shams, professor of pulmonary and infectious diseases at the University of Texas Health Science Center. "Improved methods to protect against influenza are sorely needed, particularly in the face of an impending pandemic. Development of such methods hinges on understanding host mechanisms that confer robust protection against influenza. Despite the widespread use of vaccines, influenza causes significant morbidity and mortality throughout the world, and those with poor immune systems are particularly more susceptible—such as very young, elderly, or immunocompromised individuals.”

"Unlike a vaccine, GM-CSF does not rely heavily on the body's ability to mount an immune counter-attack against a specific antigen or virus strain, but enhances the speed of local responses to virus infection and delicately balances the host immune responses," said Dr. Shams.

Related Links:
University of Texas Health Science Center




New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated MALDI-TOF MS System
EXS 3000
Homocysteine Quality Control
Liquichek Homocysteine Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.